Saturday, 17 October 2026European Markets

VITURA Stock Over 21% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of vitura (cac 40: vtr.pa) fell by a staggering 21.85% in 10 sessions from €23.8 to €18.60 at 13:07 est on friday, following the last session's upward trend. cac 40 is dropping 2.12% to €6,987.59, after four successive sessions in a row of gains.

about vitura

created in 2006, cegereal is a listed property company that invests in prime office properties in greater paris. the total value of the portfolio was estimated at €1,460 million at june 30, 2020 (excluding transfer duties). thanks to its strong commitment to environmental, social and governance issues, cegereal achieved first place among listed companies in europe in the 2019 global real estate sustainability benchmark (gresb) ranking. its entire portfolio has achieved nf hqetm exploitation and breeam in-use international certification. cegereal is a reit listed on euronext paris since 2006, in compartment b (isin: fr0010309096). the company had a market capitalization of €398 million at november 5, 2020.

earnings per share

as for profitability, vitura has a trailing twelve months eps of €1.71.

pe ratio

vitura has a trailing twelve months price to earnings ratio of 10.85. meaning, the purchaser of the share is investing €10.85 for every euro of annual earnings.

more news about vitura (vtr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com